BofA analyst Tazeen Ahmad lowered the firm’s price target on Scholar Rock (SRRK) to $49 from $53 and keeps a Buy rating on the shares. After speaking with a former director at FDA’s Office of Inspections and Investigations and with a former site inspector who previously inspected Catalent Indiana to better understand timelines and next steps for Scholar Rock following CI’s OAI classification, the firm now assumes “a bit more conservative” mid-2027 apitegromab launch timeline, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock’s Phase 2 Study on Apitegromab: A Potential Game-Changer for SMA Treatment
- Scholar Rock Faces Regulatory Concerns at Catalent Facility
- Buy Rating Affirmed for Scholar Rock Holdings Amid Regulatory Challenges and Strategic Collaborations
- Buy Rating Affirmed for Scholar Rock Holding Amid Manufacturing Challenges and Strong Market Potential
- Scholar Rock falls -12.3%